Literature DB >> 6926777

Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease.

A D Bryceson, R Woestenborghs, M Michiels, H van den Bossche.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6926777     DOI： 10.1016/0035-9203(82)90163-8

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  12 in total

1.  Experience in the treatment of osseous hydatidosis.

Authors:  G Ocete; A Guerrero; R Diaz-Peletier; J Burgos; E Bouza; C De Miguel
Journal:  Int Orthop       Date:  1986-06       Impact factor: 3.075

2.  A correlation between serum mebendazole concentrations and the aminopyrine breath test. Implications in the treatment of hydatid disease.

Authors:  A Bekhti; J Pirotte; R Woestenborghs
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

3.  Penetration of albendazole sulphoxide into hydatid cysts.

Authors:  D L Morris; J B Chinnery; G Georgiou; G Stamatakis; B Golematis
Journal:  Gut       Date:  1987-01       Impact factor: 23.059

Review 4.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

5.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

Review 6.  Diagnosis and treatment of human hydatidosis.

Authors:  H Wen; R R New; P S Craig
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

7.  Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.

Authors:  Andrew R Larsen; Ren-Yuan Bai; Jon H Chung; Alexandra Borodovsky; Charles M Rudin; Gregory J Riggins; Fred Bunz
Journal:  Mol Cancer Ther       Date:  2014-11-05       Impact factor: 6.261

8.  The effect of dose form on the bioavailability of mebendazole in man.

Authors:  M Dawson; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

9.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

10.  Pharmacokinetics of albendazole in man.

Authors:  S E Marriner; D L Morris; B Dickson; J A Bogan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.